Ironwood Pharmaceuticals Presents IW-9179 Phase 2a Data At American College of Gastroenterology 2014 Annual Scientific Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc.(NASDAQ:IRWD) announced today the presentation of initial data from a Phase IIa clinical study in functional dyspepsia with IW-9179, an investigational guanylate cyclase-C (GC-C) agonist designed to target the upper gastrointestinal (GI) tract. These data will be presented during the American College of Gastroenterology2014 Annual Scientific Meeting in Philadelphia, October 17 through October 22, 2014. Ironwood expects to initiate a Phase IIa clinical study evaluating IW-9179 in a second therapeutic area, gastroparesis, before the end of the year. Gastroparesis is an upper GI disorder that impacts an estimated 9 million Americans and is characterized by nausea, vomiting, bloating, early satiety and pain.

"As innovators in the science of guanylate cyclase-C, Ironwood created the first and only FDA-approved GC-C agonist, which is indicated for two lower gastrointestinal disorders. We are encouraged by the initial IW-9179 data and our other recent data indicating GC-C agonists may also have utility in treating upper gastrointestinal disorders," said Dr. Michael Hall, MB. BCh., senior vice president, clinical development of Ironwood. "Common upper GI disorders such as gastroparesis and functional dyspepsia remain areas where millions of suffering patients are in need of effective therapies."

The Phase IIa clinical study of IW-9179 was a randomized, double-blind study in 10 patients (six on IW-9179, four on placebo) with functional dyspepsia (FD). Patients treated with IW-9179 reported a numerically greater improvement from baseline, compared with placebo-treated patients, on six out of seven FD symptoms evaluated, including epigastric pain, epigastric bloating, postprandial fullness, early satiation, nausea and belching. The most common adverse event in IW-9179-treated patients was diarrhea. Enrollment in this study was limited by stringent enrollment criteria that sought to identify patients suffering only from GI symptoms of FD - a difficult task given that FD sufferers frequently also have symptoms of other GI disorders such as gastroesophageal reflux disease (GERD) or irritable bowel syndrome (IBS). In fact, of the 58 patients who initially met the stringent enrollment criteria and completed the 14-day pretreatment period, 78% were not qualified to enter the study treatment period owing to overlapping GI symptoms. These data inform Ironwood's continued work with gastrointestinal experts and regulatory authorities to define the path to bring forward new therapies in FD.

These data will be presented in the poster, Evaluation of Daily GI Symptoms in a Phase 2a Study of IW-9179 in Functional Dyspepsia (abstract #P1637) on Tuesday, October 21, 2014, 10:30 a.m. to 4:00 p.m., Eastern Time. Jan Tack, MD, Ph.D., Head of Clinic in the Department of Gastroenterology, and Professor of Internal Medicine at the University of Leuven, Belgium, is the lead investigator and first author.

About Functional Dyspepsia

Functional dyspepsia is an upper gastrointestinal disorder characterized by key symptoms of epigastric pain, epigastric bloating, postprandial fullness, epigastric burning, nausea, belching, and early satiety. It is estimated to impact 35 million Americans, and there are currently no treatment options approved by the Food and Drug Administration.

About Gastroparesis

Gastroparesis is an upper gastrointestinal disorder in which the muscles and/or nerves of the stomach do not function properly, which prevents the stomach from emptying. Common symptoms include nausea, vomiting, bloating, early satiety and pain. Gastroparesis is estimated to impact 9 million Americans, and there are limited treatment options available. Any trademarks referred to in this press release are the property of their respective owners. All rights reserved. About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of other countries. Our pipeline priorities include exploring further opportunities for linaclotide, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to address patient needs across the upper and lower gastrointestinal tract. Ironwood was founded in 1998 and is headquartered inCambridge, Mass. Connect with us at www.ironwoodpharma.com or on Twitter atwww.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

Help employers find you! Check out all the jobs and post your resume.

Back to news